{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:14:18Z","timestamp":1780805658809,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007565","name":"Consumers, Health, Agriculture and Food Executive Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014028","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.radonc.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T11:50:55Z","timestamp":1630151455000},"page":"114-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink"],"prefix":"10.1016","volume":"169","author":[{"given":"Josep M.","family":"Borras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-6659","authenticated-orcid":false,"given":"Ajay","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Audisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Alfons","family":"Espinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Figueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-0422","authenticated-orcid":false,"given":"Peter","family":"Naredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Panteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-3553","authenticated-orcid":false,"given":"Nicolas","family":"Pourel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Prades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9157-3730","authenticated-orcid":false,"given":"Yolande","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2021.08.002_b0005","series-title":"Purchaising to improve health systems performance","article-title":"Purchasing to improve health systems performance: drawing the lessons","author":"Figueras","year":"2005"},{"key":"10.1016\/j.radonc.2021.08.002_b0010","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(19)30794-6","article-title":"How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis on reimbursement","volume":"21","author":"Lievens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0015","unstructured":"Nolte E. How do we ensure that innovation in health service delivery and organization is implemented, sustained and spread? (Policy brief) Health Systems for Prosperity and Solidarity Series. Kluge H, Figueras J (eds.). European Observatory on Health Systems and Policies, 2018. Available from: https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0004\/380731\/pb-tallinn-03-eng.pdf [accessed 30-04-2021]."},{"key":"10.1016\/j.radonc.2021.08.002_b0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejca.2013.11.012","article-title":"Policy statement on multidisciplinary cancer care","volume":"50","author":"Borras","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.08.002_b0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.healthpol.2014.09.006","article-title":"Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes","volume":"119","author":"Prades","year":"2015","journal-title":"Health Policy"},{"key":"10.1016\/j.radonc.2021.08.002_b0030","series-title":"Pricing of cancer medicines and its impacts","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.radonc.2021.08.002_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.08.002_b0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrclinonc.2014.191","article-title":"The evolution of cancer surgery and future perspectives","volume":"12","author":"Wyld","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0045","unstructured":"National Academies of Sciences, Engineering, and Medicine. Appropriate use of radiation oncology and surgery in oncology. Washington, DC: The National Academies Press, 2016."},{"key":"10.1016\/j.radonc.2021.08.002_b0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2017.04.014","article-title":"Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper","volume":"82","author":"Aapro","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.08.002_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2015.04.021","article-title":"The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population-based analysis by the ESTRO-HERO group","volume":"116","author":"Borras","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2015.04.018","article-title":"The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis","volume":"116","author":"Borras","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0065","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1470-2045(15)00222-3","article-title":"Expanding global access to radiotherapy","volume":"16","author":"Atun","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1470-2045(20)30589-1","article-title":"Evidence based benchmarks for use of cancer surgery in High-Income countries: a population-based analysis","volume":"22","author":"Perera","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.radonc.2017.11.004","article-title":"The population benefit of evidence base radiotherapy: 5-year local control and overall survival benefits","volume":"126","author":"Hanna","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0080","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S1470-2045(18)30917-3","article-title":"Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective","volume":"20","author":"Lievens","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0085","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S026646230707033X","article-title":"Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy","volume":"23","author":"Bonastre","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.radonc.2021.08.002_b0090","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3109\/0284186X.2015.1066932","article-title":"Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology","volume":"54","author":"Lievens","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0095","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1080\/0284186X.2017.1348622","article-title":"Access to innovative radiotherapy: how to make it happen from an economic perspective?","volume":"56","author":"Lievens","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0100","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1080\/0284186X.2019.1639822","article-title":"Value-based health care - what does it mean for radiotherapy?","volume":"58","author":"Lievens","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0105","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology magnitude of clinical benefit scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0110","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0115","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0120","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology Value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2021.05.007","article-title":"Value-based radiotherapy: a new chapter of the ESTRO-HERO project","volume":"160","author":"Lievens","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0130","unstructured":"Cumberledge J. First do not harm: the report of the Independent Medicines and Medical Devices Safety Review. London: IMMDSR; July 2020. Available from: https:\/\/www.iimdsreview.org\/uk\/IMMDSReview web.pdf [accessed 30-04-2021]."},{"key":"10.1016\/j.radonc.2021.08.002_b0135","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No surgical innovation without evaluation: the IDEAL recommendations","volume":"374","author":"McCulloch","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2021.08.002_b0140","doi-asserted-by":"crossref","unstructured":"Hirst A, Philippou Y, Blazeby J, Campbell B, Campbell M, Feinberg J, et al. No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations. Ann Surg 2019; 269: 211-20.","DOI":"10.1097\/SLA.0000000000002794"},{"key":"10.1016\/j.radonc.2021.08.002_b0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fonc.2017.00059","article-title":"R-IDEAL: A framework for systematic clinical evaluation of technical innovations in radiation oncology","volume":"7","author":"Verkooijen","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0150","unstructured":"European Parliament and Council of the European Union. Regulation (EU) 2017\/745 on medical devices. Official Journal of the European Union, 5 May 2017. Available at: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32017R0745&from=EN [accessed 30-04-2021]."},{"key":"10.1016\/j.radonc.2021.08.002_b0155","unstructured":"European Medicines Agency - Human Medicines Evaluation Division. Questions & Answers on Implementation of the Medical Devices and In Vitro Diagnostic Medical Devices Regulations ((EU) 2017\/745 and (EU) 2017\/746). EMA\/37991\/2019, 21 October 2019 Rev.1. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu\/745-eu-2017\/746_en.pdf [accessed 30-04-2021]."},{"key":"10.1016\/j.radonc.2021.08.002_b0160","unstructured":"European Parliament and Council of the European Union. Regulation (EU) 2020\/561 on medical devices. Official Journal of the European Union, 24 April 2020. Available at: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32020R0561&from=EN [accessed 30-04-2021]."},{"key":"10.1016\/j.radonc.2021.08.002_b0165","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijrobp.2016.10.042","article-title":"Promoting the appropriate use of advanced radiation technologies in oncology: summary of a National Cancer Policy Forum Workshop","volume":"97","author":"Smith","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.08.002_b0170","doi-asserted-by":"crossref","unstructured":"Specchia ML, La Torre G, Calabro GE, Villari P, Grilli R, Federici A, et al. Disinvestment in cancer care: a survey investigating European countries\u2019 opinions and views. Eur J Public Health 2018; 28: 987-92.","DOI":"10.1093\/eurpub\/cky033"},{"key":"10.1016\/j.radonc.2021.08.002_b0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12913-018-2941-0","article-title":"Disinvesting in health care: an overview of HTA agencies and organizations activities at European level","volume":"18","author":"Calabro","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.radonc.2021.08.002_b0180","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clon.2020.12.008","article-title":"The financial impact on reimbursement of moderately hypofractionated postoperative radiation therapy for breast cancer: an International Consortium report","volume":"33","author":"Marta","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2021.08.002_b0185","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/hec.3525","article-title":"How should hospital reimbursement be refined to support concentration of complex care services?","volume":"27","author":"Bojke","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.radonc.2021.08.002_b0190","series-title":"Diagnosis-related groups in Europe: moving towards transparency, efficiency and quality in hospitals","article-title":"Spain: A case study on diversity of DRG use\u2013The Catalan experience","author":"Cots","year":"2011"},{"key":"10.1016\/j.radonc.2021.08.002_b0195","doi-asserted-by":"crossref","unstructured":"Stephani V, Quentin W, Van den Heede K, Van de Voorde C, Geissler A. Payment methods for hospital stays with a large variability in the care process. Brussels: KCE, 2018 (available at www.kce.be).","DOI":"10.57598\/R302C"},{"key":"10.1016\/j.radonc.2021.08.002_b0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.radonc.2017.11.005","article-title":"Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?","volume":"126","author":"Monten","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0205","series-title":"Diagnosis-related groups in Europe: Moving towards transparency, efficiency and quality in hospitals","article-title":"Moving towards transparency, efficiency and quality in hospitals: conclusions and recommendations","author":"Busse","year":"2011"},{"key":"10.1016\/j.radonc.2021.08.002_b0210","doi-asserted-by":"crossref","unstructured":"Vonlanthen R, Lodge P, Barkun JS, Farges O, Rogiers X, Soreide K. Toward a consensus on centralization in surgery. Ann Surg 2018; 268: 712-724.","DOI":"10.1097\/SLA.0000000000002965"},{"key":"10.1016\/j.radonc.2021.08.002_b0215","doi-asserted-by":"crossref","first-page":"e0195673","DOI":"10.1371\/journal.pone.0195673","article-title":"What drives centralisation in cancer care?","volume":"13","author":"Kilsdonk","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radonc.2021.08.002_b0220","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.healthpol.2018.08.016","article-title":"International comparison of minimum volume standards for hospitals","volume":"122","author":"Morche","year":"2018","journal-title":"Health Policy"},{"key":"10.1016\/j.radonc.2021.08.002_b0225","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/eurpub\/ckv237","article-title":"Improving clinical outcomes through centralization of rectal cancer surgery and clinical audit: a mixed-methods assessment","volume":"26","author":"Prades","year":"2016","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.radonc.2021.08.002_b0230","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/JTO.0000000000000421","article-title":"Stereotactic body radiotherapy for lung cancer: how much does it really cost?","volume":"10","author":"Lievens","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0235","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2019.15888","article-title":"Alternative payment for radiation oncology","volume":"322","author":"Howard","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2021.08.002_b0240","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1056\/NEJMhpr1916092","article-title":"The affordable care act at 10 years \u2013 payment and delivery system reforms","volume":"382","author":"Blumenthal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2021.08.002_b0245","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-publhealth-040119-094327","article-title":"The impact of Medicare\u2019s alternative payment models on the value of care","volume":"41","author":"Liao","year":"2020","journal-title":"Ann Rev Public Health"},{"key":"10.1016\/j.radonc.2021.08.002_b0250","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S1470-2045(17)30572-7","article-title":"Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study","volume":"18","author":"Aggarwal","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2019.06.015","article-title":"National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project","volume":"138","author":"Defourny","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0260","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.radonc.2020.01.024","article-title":"The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium","volume":"145","author":"Nevens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0265","first-page":"1040","article-title":"The state of lung cancer research: A global analysis thorac","volume":"11","author":"Aggarwal","year":"2016","journal-title":"Oncol"},{"key":"10.1016\/j.radonc.2021.08.002_b0270","first-page":"389","article-title":"Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?","volume":"119","author":"Thompson","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2021.08.002_b0275","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1740774517725697","article-title":"Testing many treatments within a single protocol over 10 years at MRC CTU at UCL: Multi-arm, multi- stage platform, umbrella and basket protocols","volume":"14","author":"Parmar","year":"2017","journal-title":"Clin Trials"},{"key":"10.1016\/j.radonc.2021.08.002_b0280","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","article-title":"Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma","volume":"108","author":"Liu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.08.002_bib281","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","article-title":"Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework of coverage decisions.","volume":"15","author":"Wlaker","year":"2012","journal-title":"Value Health"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021066846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021066846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:20:59Z","timestamp":1759123259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814021066846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":57,"alternative-id":["S0167814021066846"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2021.08.002","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd. on behalf of British Association of Surgical Oncology and European Society of Surgical Oncology, and Elsevier B.V.","name":"copyright","label":"Copyright"}]}}